Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/39718
metadata.artigo.dc.title: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
metadata.artigo.dc.title.alternative: Hidroxicloroquina e azitromicina como tratamento do COVID-19: resultados de um ensaio clínico aberto não randomizado
metadata.artigo.dc.creator: Gautret, Philippe
Lagier, Jean-Christophe
Parola, Philippe
Hoang, Van Thuan
Meddeb, Line
Mailhe, Morgane
Doudier, Barbara
Courjon, Johan
Giordanengo, Valérie
Vieira, Vera Esteves
Dupont, Hervé Tissot
Honoré, Stéphane
Colson, Philippe
Chabrière, Eric
Scola, Bernard La
Rolain, Jean-Marc
Brouqui, Philippe
Raoult, Didier
metadata.artigo.dc.subject: COVID-19
Coronavirus
Hydroxychloroquine
Azithomycin
SARS-CoV-2
Hidroxicloroquina
Azitromicina
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: 2020
metadata.artigo.dc.identifier.citation: GAUTRET, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, [S. l.], 2020. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105949.
metadata.artigo.dc.description.resumo: Contexto Verificou-se que a cloroquina e a hidroxicloroquina são eficientes no tratamento de SARS-CoV-2, e foram reportadas serem eficientes em pacientes chineses com COV-19. Nós avaliamos o papel da hidroxicloroquina na carga viral respiratória. Pacientes e Métodos Pacientes franceses com COVID-19 confirmada foram incluídos em um protocolo de braço único, do começo de março até 16 de março, para receber 600mg de hidroxicloroquina diariamente e as cargas virais em swabs de nasofaringe foram testadas diariamente no ambiente hospitalar. Dependendo da apresentação clínica, a azitromicina era adicionada ao tratamento. Pacientes não tratados de outros centros e casos que recusaram o protocolo foram incluídos como controles negativos. A presença ou a ausência do vírus no sexto dia pós inclusão foram consideradas os desfechos. Resultados Seis pacientes eram assintomáticos, vinte e dois tinham sintomas de infecção de trato respiratório superior e oito tinham sintomas de trato respiratório inferior. Vinte casos foram tratados neste estudo e mostraram uma redução significativa da carga viral no sexto dia após a inclusão em comparação com os controles, e uma duração da condição de portador muito menor do que a média reportada na literatura em pacientes não tratados. A azitromicina adicionada à hidroxicloroquina foi significantemente mais eficiente para a eliminação viral. Conclusão Apesar do tamanho pequeno da amostra, nossa pesquisa mostra que o tratamento com hidroxicloroquina é significantemente associada com redução/desaparecimento da carga viral em pacientes com COVID-19, e seu efeito é reforçado pela azitromicina.
metadata.artigo.dc.description.abstract: Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. Patients and methods French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. Results Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. Conclusion Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S0924857920300996#!
http://repositorio.ufla.br/jspui/handle/1/39718
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.